ALBLU Fundamental Analysis - BLUELINEA

Fundamental Rating

Taking everything into account, ALBLU scores 1 out of 10 in our fundamental rating. ALBLU was compared to 65 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALBLU have multiple concerns. ALBLU does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALBLU had negative earnings in the past year.

In the past year ALBLU had a positive cash flow from operations.

ALBLU had negative earnings in each of the past 5 years.

In the past 5 years ALBLU reported 4 times negative operating cash flow.

1.2 Ratios

ALBLU has a worse Return On Assets (-8.00%) than 72.31% of its industry peers.

ALBLU's Return On Equity of -107.04% is on the low side compared to the rest of the industry. ALBLU is outperformed by 81.54% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8%
ROE	-107.04%
ROIC	N/A

ROA(3y)-13.33%

ROA(5y)-23.44%

ROE(3y)-62.14%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of ALBLU (98.54%) is better than 100.00% of its industry peers.

In the last couple of years the Gross Margin of ALBLU has grown nicely.

The Profit Margin and Operating Margin are not available for ALBLU so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	98.54%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y7.37%

GM growth 5Y2.44%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALBLU does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ALBLU has about the same amount of shares outstanding.

The number of shares outstanding for ALBLU has been increased compared to 5 years ago.

Compared to 1 year ago, ALBLU has a worse debt to assets ratio.

2.2 Solvency

ALBLU has an Altman-Z score of -2.97. This is a bad value and indicates that ALBLU is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -2.97, ALBLU is doing worse than 84.62% of the companies in the same industry.

A Debt/Equity ratio of 5.83 is on the high side and indicates that ALBLU has dependencies on debt financing.

ALBLU has a worse Debt to Equity ratio (5.83) than 89.23% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	5.83
Debt/FCF	N/A
Altman-Z	-2.97

ROIC/WACCN/A

WACC7.15%

2.3 Liquidity

ALBLU has a Current Ratio of 0.37. This is a bad value and indicates that ALBLU is not financially healthy enough and could expect problems in meeting its short term obligations.

ALBLU has a worse Current ratio (0.37) than 90.77% of its industry peers.

A Quick Ratio of 0.33 indicates that ALBLU may have some problems paying its short term obligations.

ALBLU has a Quick ratio of 0.33. This is amonst the worse of the industry: ALBLU underperforms 89.23% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.37
Quick Ratio	0.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALBLU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.46%, which is quite impressive.

ALBLU shows a small growth in Revenue. In the last year, the Revenue has grown by 7.97%.

Measured over the past years, ALBLU shows a quite strong growth in Revenue. The Revenue has been growing by 8.42% on average per year.

EPS 1Y (TTM)55.46%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%38.21%

Revenue 1Y (TTM)7.97%

Revenue growth 3Y7.87%

Revenue growth 5Y8.42%

Sales Q2Q%17.98%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALBLU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

ALBLU's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALBLU is cheaper than 86.15% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	8.78

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALBLU does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

BLUELINEA

EPA:ALBLU (12/24/2025, 7:00:00 PM)

0.48

+0.01 (+2.13%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners58%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap8.84M

Revenue(TTM)10.26M

Net Income(TTM)-760.00K

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.86
P/FCF	N/A
P/OCF	25.26
P/B	12.45
P/tB	N/A
EV/EBITDA	8.78

EPS(TTM)-0.06

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.05

FCFYN/A

OCF(TTM)0.02

OCFY3.96%

SpS0.56

BVpS0.04

TBVpS-0.26

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-8%
ROE	-107.04%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	98.54%
FCFM	N/A

ROA(3y)-13.33%

ROA(5y)-23.44%

ROE(3y)-62.14%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y7.37%

GM growth 5Y2.44%

F-Score5

Asset Turnover1.08

Health

		Industry Rank	Sector Rank
Debt/Equity	5.83
Debt/FCF	N/A
Debt/EBITDA	3.54
Cap/Depr	71.51%
Cap/Sales	12.96%
Interest Coverage	N/A
Cash Conversion	29.91%
Profit Quality	N/A
Current Ratio	0.37
Quick Ratio	0.33
Altman-Z	-2.97

F-Score5

WACC7.15%

ROIC/WACCN/A

Cap/Depr(3y)147.1%

Cap/Depr(5y)113.92%

Cap/Sales(3y)22.59%

Cap/Sales(5y)17.29%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)55.46%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%38.21%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)7.97%

Revenue growth 3Y7.87%

Revenue growth 5Y8.42%

Sales Q2Q%17.98%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y56.06%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y80.44%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y116.06%

OCF growth 3YN/A

OCF growth 5YN/A

BLUELINEA / ALBLU.PA FAQ

What is the fundamental rating for ALBLU stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALBLU.PA.

Can you provide the valuation status for BLUELINEA?

ChartMill assigns a valuation rating of 1 / 10 to BLUELINEA (ALBLU.PA). This can be considered as Overvalued.

How profitable is BLUELINEA (ALBLU.PA) stock?

BLUELINEA (ALBLU.PA) has a profitability rating of 2 / 10.

BLUELINEA (ALBLU.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BLUELINEA / ALBLU.PA FAQ

What is the fundamental rating for ALBLU stock?

Can you provide the valuation status for BLUELINEA?

How profitable is BLUELINEA (ALBLU.PA) stock?